H.C. Wainwright analyst Mitchell Kapoor lowered the firm’s price target on Halozyme to $60 from $61 and keeps a Buy rating on the shares post the Q2 report.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on HALO:
- Halozyme raises FY23 non-GAAP EPS view to $2.65-$2.75 from $2.50-$2.65
- Halozyme reports Q2 non-GAAP EPS 74c, consensus 63c
- HALOZYME REPORTS SECOND QUARTER 2023 FINANCIAL AND OPERATING RESULTS
- HALO Upcoming Earnings Report: What to Expect?
- Halozyme initiated with a Buy at H.C. Wainwright
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue